In vivo assays further suggested that topotecan has an equivalent effect to genetic silencing of USP22 in inhibiting melanoma lung metastasis, but topotecan could not further decrease lung metastasis in the absence of USP22 (Figure 6N). The gene discussed is USP22; the disease is melanoma.